2022
DOI: 10.5603/ep.a2022.0033
|View full text |Cite
|
Sign up to set email alerts
|

Tumour-induced osteomalacia (TIO)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 2 publications
0
3
0
Order By: Relevance
“…A series of six patients diagnosed with TIO originating from one diagnostic centre has been presented here. Although the number of patients is small, it is worth mentioning that approximately 1000 cases have been reported in the medical literature so far [ 1 ], including only five single reports from Poland [ 12 , 13 , 14 , 15 , 16 , 17 ]. All patients presented in this study demonstrated similar clinical signs including severe pain, proximal muscle weakness, fractures, loss of height, and deterioration in mobility.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A series of six patients diagnosed with TIO originating from one diagnostic centre has been presented here. Although the number of patients is small, it is worth mentioning that approximately 1000 cases have been reported in the medical literature so far [ 1 ], including only five single reports from Poland [ 12 , 13 , 14 , 15 , 16 , 17 ]. All patients presented in this study demonstrated similar clinical signs including severe pain, proximal muscle weakness, fractures, loss of height, and deterioration in mobility.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, the [ 68 Ga]Ga-DOTATATE PET/CT could be used as a follow-up imaging modality, as in the two presented cases, it was able to indicate local recurrence after surgery. It should be underlined that [ 68 Ga]Ga-DOTATATE PET/CT was not applied in the previously published cases from Poland; tumour localization was made by palpation [13], [ 18 F]FDG-PET/CT [14], MR, and CT [15], as well as the somatostatin receptor scintigraphy [16]. It is noteworthy that for most of the described cases, the tumours were located in the pelvic region, while data from the literature reported tumours located in the pelvis in only 10.3% of patients [18].…”
Section: Discussionmentioning
confidence: 99%
“…the difficulty of localising the lesion and active vitamin D and phosphate substitution [5]. In recent years, attempts to treat the syndrome with burosumab (KRN23), i.e.…”
Section: Clinical Vignettementioning
confidence: 99%